Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine…
TLDR
The suppression of phosphotyrosine STAT3 levels resulted in the inhibition of STAT3 DNA binding and STAT3-mediated but not serum response element-mediated gene transcription, giving strong support for pharmacologically targeting the JAK/STAT3 signaling pathway for anticancer drug discovery.
View on PubMed
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
TLDR
Findings strongly suggest that the antitumor activity of S3I-201 is mediated in part through inhibition of aberrant Stat3 activation and provide the proof-of-concept for the potential clinical use of Stat3 inhibitors such as S3i-201 in tumors harboring aberrantStat3.
View on Publisher
Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt
TLDR
The discovery of a small molecule Akt pathway inhibitor, Akt/protein kinase B signaling inhibitor-2 (API-2) is reported, providing strong evidence for pharmacologically targeting Akt for anticancer drug discovery.
View on Publisher
Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor
TLDR
NSC-87877 is identified as the first PTP inhibitor capable of inhibiting Shp2 PTP in cell cultures without a detectable off-target effect and provides the first pharmacological evidence that Shp 2 mediates EGF-induced Erk1/2 MAP kinase activation.
View on Publisher
Targeting protein prenylation for cancer therapy
TLDR
This Review discusses the mechanisms by which FT and GGT1 inhibitors (FTIs and G GTIs, respectively) affect signal transduction pathways, cell cycle progression, proliferation and cell survival, and strategies to overcome this.
View on Nature
Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*)
TLDR
The results demonstrate that FTI-277 blocks Ras oncogenic signaling by accumulating inactive Ras/Raf complexes in the cytoplasm, hence preventing constitutive activation of the MAPK cascade.
View on Publisher
The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis
TLDR
It is demonstrated that FTI-277 inhibits phosphatidylinositol 3-OH kinase (PI 3-kinase)/AKT2-mediated growth factor- and adhesion-dependent survival pathways and induces apoptosis in human cancer cells that overexpress AKT2.
View on Publisher
Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin,…
TLDR
It is demonstrated that this highly potent and selective novel class of non-thiol-containing peptidomimetic inhibitors of FTase inhibits human tumor growth in whole animals and that combination therapy with cytotoxic agents is more beneficial than monotherapy.
View on PubMed
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity
TLDR
The authors have identified errors and addressed them in the article entitled ‘Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity’.
View on Nature
Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human…
TLDR
Soft agar experiments demonstrated that in all the human tumor cell lines tested inhibition of K-Ras prenylation was not necessary for inhibition of anchorage-independent growth, and that inhibition of human tumor growth in soft agar does not require inhibition of oncogenic K- Ras processing.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License